search
Back to results

Thiamine Supplementation in Patients With Septic Shock

Primary Purpose

Septic Shock, Shock, Septic, Lactic Acidosis

Status
Withdrawn
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Thiamine
Placebos
Sponsored by
The Cleveland Clinic
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Septic Shock

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age>18
  • Sepsis (defined as presence of two or more SIRS criteria with documented or suspected infection)
  • SIRS: Systemic Inflammatory Response Syndrome (SIRS) is the occurrence of at least two of the following criteria: temperature >38.0ºC or <36.0ºC, heart rate >90 beats/minute, respiratory rate >20 breaths/minute, white blood cell count >12,000 or <4000.
  • Lactate >3mmol/L at the time of consent and randomization
  • Hypotension (systolic blood pressure <90mmHg) after a >2L fluid bolus
  • Vasopressor dependence (defined as the continuous infusion of norepinephrine, dopamine, phenylephrine, vasopressin or epinephrine.)

Exclusion Criteria:

  • Known cirrhosis or chronic liver disease
  • Current thiamine supplementation
  • Clinical indication for thiamine (e.g. Alcohol abuse)
  • Comfort measures only designation
  • Inability to provide consent
  • Other causes for lactate elevation (seizure, use of medications that can cause lactic acidosis such as metformin, linezolid and anti-retrovirals, carbon monoxide, known or suspected bowel or limb ischemia, cardiac arrest prior to enrollment)

Sites / Locations

  • Cleveland Clinic Florida

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Thiamine Supplementation Group

Placebo Group

Arm Description

Patients will receive 200mg thiamine in 50mL of 5% dextrose once daily for 7 days or until discharge from the intensive care unit.

Patients will receive placebo (50mL 5% dextrose) once daily for 7 days or until discharge from the intensive care unit.

Outcomes

Primary Outcome Measures

Time to Reversal of Shock
Number of hours that the patient required vasopressors
Time to Normalization of Lactic Acidosis

Secondary Outcome Measures

ICU Mortality
Death occurring during the ICU stay
ICU Length of Stay
Number of days that the patient remains in the ICU after admission to the ICU

Full Information

First Posted
February 16, 2017
Last Updated
March 14, 2019
Sponsor
The Cleveland Clinic
search

1. Study Identification

Unique Protocol Identification Number
NCT03122678
Brief Title
Thiamine Supplementation in Patients With Septic Shock
Official Title
Thiamine Supplementation in Patients With Septic Shock: A Randomized, Double Blind, Placebo Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
March 2019
Overall Recruitment Status
Withdrawn
Why Stopped
No participant enrolled
Study Start Date
November 5, 2016 (Actual)
Primary Completion Date
March 14, 2019 (Anticipated)
Study Completion Date
March 14, 2019 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
The Cleveland Clinic

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
To determine if intravenous thiamine would decrease the time to reversal of shock in patients with septic shock.
Detailed Description
Patients will be randomized to thiamine supplementation or placebo in a 1:1 ratio. Randomization will be done by the hospital pharmacy department whom will be the only unblinded participants. Patients will receive 200mg thiamine in 50mL of 5% dextrose or matching placebo (50mL 5% dextrose) once daily for 7 days or until discharge from the intensive care unit. The drug will be mixed by the pharmacy. Administration will be done in the patients room in the intensive care unit by the patient's assigned nurse. Blood will be collected on admission to the hospital in order to determine baseline lactate level and study eligibility. The measurement of lactate is standard of care in patients with sepsis. Thiamine level will be collected upon enrollment into the study. The ICU nurse or emergency room nurse taking care of the patient at the time of enrollment will draw the blood sample. Standard procedure for measuring thiamine levels will be maintained including protecting the blood sample from light and keeping it on ice while it is delivered to the lab. Serum lactate will be measured daily for 7 days or until discharge from the intensive care unit. The serial measurement of serum lactate is considered standard of care in patients with sepsis.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Septic Shock, Shock, Septic, Lactic Acidosis, Thiamine Deficiency

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Thiamine Supplementation Group
Arm Type
Experimental
Arm Description
Patients will receive 200mg thiamine in 50mL of 5% dextrose once daily for 7 days or until discharge from the intensive care unit.
Arm Title
Placebo Group
Arm Type
Placebo Comparator
Arm Description
Patients will receive placebo (50mL 5% dextrose) once daily for 7 days or until discharge from the intensive care unit.
Intervention Type
Drug
Intervention Name(s)
Thiamine
Other Intervention Name(s)
Vitamin B1
Intervention Type
Drug
Intervention Name(s)
Placebos
Other Intervention Name(s)
50mL 5% dextrose
Primary Outcome Measure Information:
Title
Time to Reversal of Shock
Description
Number of hours that the patient required vasopressors
Time Frame
7 days
Title
Time to Normalization of Lactic Acidosis
Time Frame
7 days
Secondary Outcome Measure Information:
Title
ICU Mortality
Description
Death occurring during the ICU stay
Time Frame
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months
Title
ICU Length of Stay
Description
Number of days that the patient remains in the ICU after admission to the ICU
Time Frame
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age>18 Sepsis (defined as presence of two or more SIRS criteria with documented or suspected infection) SIRS: Systemic Inflammatory Response Syndrome (SIRS) is the occurrence of at least two of the following criteria: temperature >38.0ºC or <36.0ºC, heart rate >90 beats/minute, respiratory rate >20 breaths/minute, white blood cell count >12,000 or <4000. Lactate >3mmol/L at the time of consent and randomization Hypotension (systolic blood pressure <90mmHg) after a >2L fluid bolus Vasopressor dependence (defined as the continuous infusion of norepinephrine, dopamine, phenylephrine, vasopressin or epinephrine.) Exclusion Criteria: Known cirrhosis or chronic liver disease Current thiamine supplementation Clinical indication for thiamine (e.g. Alcohol abuse) Comfort measures only designation Inability to provide consent Other causes for lactate elevation (seizure, use of medications that can cause lactic acidosis such as metformin, linezolid and anti-retrovirals, carbon monoxide, known or suspected bowel or limb ischemia, cardiac arrest prior to enrollment)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jinesh Mehta, MD
Organizational Affiliation
Cleveland Clinic Florida
Official's Role
Principal Investigator
Facility Information:
Facility Name
Cleveland Clinic Florida
City
Weston
State/Province
Florida
ZIP/Postal Code
33331
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Thiamine Supplementation in Patients With Septic Shock

We'll reach out to this number within 24 hrs